The effect of zoledronic acid on serum dickkopf-1, osteoprotegerin, and RANKL in patients with paget's disease of bone

Hormone and Metabolic Research

Volumn 41, Issue 11, 2009, Pages 846-850

  Polyzos, S A ^a,f   Anastasilakis, A D ^b   Efstathiadou, Z ^a   Kita, M ^a   Litsas, I ^a   Avramidis, A ^a   Arsos, G ^c   Moralidis, E ^c   Gerou, S ^d   Pavlidou, V ^d   Papatheodorou, A ^e   Terpos, E ^e  

^a Ippokration Hospital Thessaloniki   (Greece)

^b 424 General Army Hospital   (Greece)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^d Laboratories Analysis   (Greece)

^e 251 GENERAL AIR FORCE HOSPITAL   (Greece)

^f NONE   (Greece)

Author keywords

Dickkopf; Nuclear factor kappa B; Osteoprotegerin; Paget's disease; RANKL; Zoledronic acid

Indexed keywords

ALKALINE PHOSPHATASE; CALCIUM CARBONATE; CARBOXY TERMINAL TELOPEPTIDE; DICKKOPF 1 PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; TECHNETIUM 99M; TECHNETIUM 99M HYDROXYMETHYLENE BISPHOSPHONATE; UNCLASSIFIED DRUG; VITAMIN D; ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BODY MASS; BONE SCINTISCANNING; CARBOXY TERMINAL SEQUENCE; CLINICAL ARTICLE; CLINICAL EVALUATION; COHORT ANALYSIS; CONTROLLED STUDY; CROSS LINKING; FEMALE; HUMAN; MALE; PAGET BONE DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SKULL INJURY;

AGED; CASE-CONTROL STUDIES; COHORT STUDIES; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; OSTEITIS DEFORMANS; OSTEOPROTEGERIN; PROSPECTIVE STUDIES; RANK LIGAND;

EID: 70349324551     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0029-1233491     Document Type: Article

References (25)

1. Cundy T, Bolland M. Paget disease of bone. Trends Endocrinol Metab 2008; 19: 246-253
2. Ralston SH, Langston AL, Reid IR. Pathogenesis and management of Paget's disease of bone. Lancet 2008; 372: 155-163 (Pubitemid 351952259)
3. Devogelaer JP, Bergmann P, Body JJ, Boutsen Y, Goemaere S, Kaufman JM, Reginster JY, Rozenberg S, Boonen S. Management of patients with Paget's disease: a consensus document of the Belgian Bone Club. Osteoporos Int 2008; 19: 1109-1117
4. Selby PL. Guidelines for the diagnosis and management of Paget's disease: a UK perspective. J Bone Miner Res 2006; 21 (Suppl 2): 92-93
5. Xu J, Wu HF, Ang ES, Yip K, Woloszyn M, Zheng MH, Tan RX. NF-kappaB modulators in osteolytic bone diseases. Cytokine Growth Factor Rev 2009; 20: 7-17
6. Vega D, Maalouf NM, Sakhaee K. The role of receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/osteoprotegerin: clinical implications. J Clin Endocrinol Metab 2007; 92: 4514-4521 (Pubitemid 350223419)
7. Martini C, Gennari L, Merlotti D, Salvadori S, Franci MB, Campagna S, Avanzati A, De PV, Valleggi F, Nuti R. Serum OPG and RANKL levels before and after intravenous bisphosphonate treatment in Paget's disease of bone. Bone 2007; 40: 457-463 (Pubitemid 46054544)
8. Alvarez L, Peris P, Guanabens N, Vidal S, Ros I, Pons F, Filella X, Monegal A, Munoz-Comez J, Ballesta AM. Serum osteoprotegerin and its ligand in Paget's disease of bone: relationship to disease activity and effect of treatment with bisphosphonates. Arthritis Rheum 2003; 48: 824-828 (Pubitemid 36302021)
9. Mossetti G, Rendina D, De FC, Viceconti R, Di DG, Cioffi M, Postiglione L, Nunziata V. Interleukin-6 and osteoprotegerin systems in Paget's disease of bone: relationship to risedronate treatment. Bone 2005; 36: 549-554 (Pubitemid 40403853)
10. Suzuki A, Ozono K, Kubota T, Kondou H, Tachikawa K, Michigami T. PTH/cAMP/PKA signaling facilitates canonical Wnt signaling via inactivation of glycogen synthase kinase-3beta in osteoblastic Saos-2 cells. J Cell Biochem 2008; 104: 304-317
11. Krishnan V, Bryant HU, Macdougald OA. Regulation of bone mass by Wnt signaling. J Clin Invest 2006; 116: 1202-1209
12. Fujita K, Janz S. Attenuation of WNT signaling by DKK-1 and -2 regulates BMP2-induced osteoblast differentiation and expression of OPG, RANKL and M-CSF. Mol Cancer 2007; 6: 71-71
13. Naot D, Bava U, Matthews B, Callon KE, Gamble GD, Black M, Song S, Pitto RP, Cundy T, Cornish J, Red IR. Differential gene expression in cultured osteoblasts and bone marrow stromal cells from patients with Paget's disease of bone. J Bone Miner Res 2007; 22: 298-309 (Pubitemid 46167800)
14. Hosking D, Lyles K, Brown JP, Fraser WD, Miller P, Curiel MD, Devogelaer JP, Hooper M, Su C, Zelenakas K, Pak J, Fashola T, Saidi Y, Eriksen EF, Reid IR. Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate. J Bone Miner Res 2007; 22: 142-148 (Pubitemid 46032607)
15. Reid IR, Miller P, Lyles K, Fraser W, Brown JP, Saldi Y, Mesenbrink P, Su G, Pak J, Zelenakas K, Luchi M, Richardson P, Hosking D. Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. N Engl J Med 2005; 353: 898-908 (Pubitemid 41247929)
16. Khan SA, McCloskey EV, Eyres KS, Nakatsuka K, Sirtori P, Orgee J, Coombes G, Kanis JA. Comparison of three intravenous regimens of clodronate in Paget disease of bone. J Bone Miner Res 1996; 11: 178-182 (Pubitemid 26054175)
17. Kaiser M, Mieth M, Liebisch P, Oberlander R, Rademacher J, Jakob C, Kleeberg L, Fleissner C, Braendle E, Peters M, Stover D, Sezer O, Heider U. Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma. Eur J Haematol 2008; 80: 490-494 (Pubitemid 351677464)
18. Voorzanger-Rousselot N, Goehrig D, Journe F, Doriath V, Body JJ, Clezardin P, Garnero P. Increased Dickkopf-1 expression in breast cancer bone metastases. Br J Cancer 2007; 97: 964-970 (Pubitemid 47519305)
19. Neale SD, Smith R, Wass JA, Athanasou NA. Osteoclast differentiation from circulating mononuclear precursors in Paget's disease is hypersensitive to 1,25-dihydroxyvitamin D(3) and RANKL. Bone 2000; 27: 409-416 (Pubitemid 30658125)
20. Viereck V, Emons G, Lauck V, Frosch KH, Blaschke S, Grundker C, Hofbauer LC. Bisphosphonates Pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. Biochem Biophys Res Commun 2002; 291: 680-686
21. Pan B, Farrugia AN, To LB, Findlay DM, Green J, Lynch K, Zannettino AC. The nitrogen-containing bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblast-like cells by activating TNF-alpha converting enzyme (TACE). J Bone Miner Res 2004; 19: 147-154 (Pubitemid 41295147)
22. Anastasilakis AD, Goulis DG, Polyzos SA, Gerou S, Koukoulis G, Kita M, Avramidis A. Serum osteoprotegerin and RANKL are not specifically altered in women with postmenopausal osteoporosis treated with teriparatide or risedronate: a randomized, controlled trial. Horm Metab Res 2008; 40: 281-285
23. Kearns AE, Khosla S, Kostenuik PJ. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev 2008; 29: 155-192
24. Avramidis A, Polyzos SA, Moralidis E, Arsos G, Efstathiadou Z, Karakatsanis K, Grollios G, Kita M. Scintigraphic, biochemical, and clinical response to zoledronic acid treatment in patients with Paget's disease of bone. J Bone Miner Metab 2008; 26: 635-641
25. Wellington K, Goa KL. Zoledronic acid: a review of its use in the management of bone metastases and hypercalcaemia of malignancy. Drugs 2003; 63: 417-437